Acamprosate/baclofen

Drug Profile

Acamprosate/baclofen

Alternative Names: PXT 864; PXT-001; PXT-002

Latest Information Update: 16 Dec 2016

Price : $50

At a glance

  • Originator BioSystems International; INSERM; Pharnext; University of Bordeaux
  • Developer Pharnext
  • Class Alkanesulfonic-acids; Aminobutyric acids; Antiparkinsonians; Antispastics; Muscle relaxants; Nootropics; Small molecules
  • Mechanism of Action GABA B receptor agonists; GABA receptor agonists; Glutamate receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Alzheimer's disease
  • Phase I Amyotrophic lateral sclerosis; Parkinson's disease
  • Discontinued Memory disorders

Most Recent Events

  • 13 Dec 2016 Efficacy and adverse event data from a phase II trial in Alzheimer's disease released by Pharnext
  • 16 Feb 2016 Pharnext completes a phase I trial in Amyotrophic lateral sclerosis in France
  • 01 Dec 2015 Pharnext completes the PLEODIAL-II phase II trial for Alzheimer's disease (Treatment-naive) in France (NCT02361242)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top